ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag industry cancer biobusiness genetics genomics

A vet and technician take a sample from a dog for use in PetDx’s OncoK9 test, which screens cell-free DNA for genomic alterations associated with cancer.
The Pet Health Industry Takes on Canine Cancer
Diana Kwon | Oct 17, 2022 | 9 min read
Advanced genomic tools have provided biotech companies new approaches to help our furry friends—but experts say several limitations remain.
Women looks at computer screen in a lab coat and mask
Quest for Research Freedom Fuels African Biotech Boom
Linda Nordling | Jul 1, 2021 | 6 min read
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Learning from Iceland’s Model for Genetic Research
Catherine Offord | Jun 1, 2017 | 8 min read
The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020 | 8 min read
There’s a new cell-based cancer immunotherapy on the block.
The Growth of Iowa Biotech
Jenny Rood | Aug 1, 2016 | 7 min read
The state’s industry draws inspiration from medicine as well as agriculture.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Braving the IPO Drought
Megan Scudellari | Mar 1, 2012 | 7 min read
Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard

Run a Search

ADVERTISEMENT